GB0815788D0 - Therapeutic antibodies - Google Patents

Therapeutic antibodies

Info

Publication number
GB0815788D0
GB0815788D0 GBGB0815788.5A GB0815788A GB0815788D0 GB 0815788 D0 GB0815788 D0 GB 0815788D0 GB 0815788 A GB0815788 A GB 0815788A GB 0815788 D0 GB0815788 D0 GB 0815788D0
Authority
GB
United Kingdom
Prior art keywords
therapeutic antibodies
antibodies
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0815788.5A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Priority to GBGB0815788.5A priority Critical patent/GB0815788D0/en
Publication of GB0815788D0 publication Critical patent/GB0815788D0/en
Priority to PCT/GB2009/051084 priority patent/WO2010023482A2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
GBGB0815788.5A 2008-08-29 2008-08-29 Therapeutic antibodies Ceased GB0815788D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0815788.5A GB0815788D0 (en) 2008-08-29 2008-08-29 Therapeutic antibodies
PCT/GB2009/051084 WO2010023482A2 (en) 2008-08-29 2009-08-28 Therapeutic antibody

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0815788.5A GB0815788D0 (en) 2008-08-29 2008-08-29 Therapeutic antibodies

Publications (1)

Publication Number Publication Date
GB0815788D0 true GB0815788D0 (en) 2008-10-08

Family

ID=39865969

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0815788.5A Ceased GB0815788D0 (en) 2008-08-29 2008-08-29 Therapeutic antibodies

Country Status (2)

Country Link
GB (1) GB0815788D0 (en)
WO (1) WO2010023482A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012138768A2 (en) * 2011-04-04 2012-10-11 Trustees Of Dartmouth College Anti-cd154 antibodies having impaired fcr binding and/or complement binding properties and the use thereof in immune therapies
US9028826B2 (en) 2011-04-04 2015-05-12 The Trustees Of Dartmouth College Methods of immune therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties
US9321833B2 (en) 2011-04-04 2016-04-26 The Trustees Of Dartmouth College Methods of therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties
LT2766395T (en) 2011-10-13 2020-03-25 Bristol-Myers Squibb Company Antibody polypeptides that antagonize cd40l
MA41459A (en) 2015-02-03 2017-12-12 Als Therapy Development Inst ANTI-CD40L ANTIBODIES AND METHODS FOR TREATING CD40L ILLNESSES OR DISORDERS
US10906976B2 (en) * 2015-12-01 2021-02-02 The Chinese University Of Hong Kong Induction of immunotolerance to improve acceptance of tissue derived from pluripotent stem cells
AU2018271915A1 (en) * 2017-05-24 2019-11-28 Als Therapy Development Institute Therapeutic anti-CD40 ligand antibodies
KR20210006301A (en) * 2019-07-08 2021-01-18 주식회사 프로젠 A novel fusion protein and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2291156A1 (en) * 1997-05-17 1998-11-26 Biogen, Inc. Use of a cd40:cd154 binding interruptor to prevent counter adaptive immune responses, particularly graft rejection
AU748533B2 (en) * 1997-06-11 2002-06-06 United States Of America As Represented By The Secretary Of The Navy, The Composition and method to prevent graft rejection and other counter-adaptive T lymphocyte mediated immune responses
DE69916807T2 (en) * 1998-02-04 2005-01-13 The General Hospital Corp., Boston COSTIMULATORY BLOCKADE AND MIXED CHIMERISM IN ALLOTRANSPLANTATIONS
CA2358435A1 (en) * 1999-01-08 2000-07-13 Stuart J. Knechtle Methods of prolonging transplant survival using immunotoxins and costimulation blockade of cd154 and cd28
CA2410786A1 (en) * 2000-06-02 2001-12-13 Regents Of The University Of Minnesota Immunotherapeutic method to prevent islet cell rejection
WO2005003175A2 (en) * 2003-06-13 2005-01-13 Biogen Idec Ma Inc. Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof

Also Published As

Publication number Publication date
WO2010023482A3 (en) 2010-06-24
WO2010023482A2 (en) 2010-03-04

Similar Documents

Publication Publication Date Title
PL2949666T3 (en) Human anti-alpha-synuclein antibodies
ZA201102119B (en) Improved antibody libraies
EP2241578A4 (en) Anti-cldn6 antibody
EP2320907A4 (en) Therapeutic compounds
GB0708002D0 (en) Antibodies
EP2207803A4 (en) Cd9-specific human antibodies
GB0821100D0 (en) Antibodies
EP2337798A4 (en) Bsa-specific antibodies
EP2268285A4 (en) Therapeutic compounds
GB0806794D0 (en) Therapeutic compounds
GB0718737D0 (en) Antibodies
ZA201006099B (en) Anti-tyrp1 antibodies
GB0813740D0 (en) Therapeutic compounds
IL211670A (en) Formulations comprising therapeutic anti-steap-1 antibodies
GB0804755D0 (en) Therapeutic compounds
GB0815788D0 (en) Therapeutic antibodies
ZA201007976B (en) Anti-pirb antibodies
EP2344533A4 (en) Tmprss4-specific human antibody
GB0818356D0 (en) Antibodies
EP2324059A4 (en) Anti-pamp therapeutic antibodies
GB0902916D0 (en) Antibody therapy
GB0911770D0 (en) Antibody
HRP20190159T1 (en) Human anti-alpha-synuclein antibodies
GB0806230D0 (en) Antibodies
GB0823562D0 (en) Antibodies

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)